Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Wiestner

Showing results (131-140 of 149) with videos related to

Pageof 15
Sort By:
Blood|October 14, 2010
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemiaYair Herishanu, Patricia Pérez-Galán, Delong Liu, et al.
Blood|November 14, 2022
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenograftsDeyi Zhang, Hailey M Harris, Jonathan Chen, et al.
Blood|January 8, 2025
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cellsSivasubramanian Baskar, Haiyong Peng, Erika M Gaglione, et al.
Leukemia & Lymphoma|March 3, 2021
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 studySanjal Desai, Clifton Mo, Erika M Gaglione, et al.
Blood|February 28, 2018
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 studyInhye E Ahn, Mohammed Z H Farooqui, Xin Tian, et al.
Blood|March 18, 2021
MARCKS affects cell motility and response to BTK inhibitors in CLLLaura Beckmann, Valeska Berg, Clarissa Dickhut, et al.
Leukemia & Lymphoma|March 11, 2017
Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemiaFie J Vojdeman, Sarah E M Herman, Nikolai Kirkby, et al.
The Lancet. Oncology|January 4, 2015
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trialMohammed Z H Farooqui, Janet Valdez, Sabrina Martyr, et al.
The Journal of Experimental Medicine|January 6, 2018
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemiaErika Tissino, Dania Benedetti, Sarah E M Herman, et al.
Cancer Research|August 24, 2012
Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical featuresAlba Navarro, Guillem Clot, Cristina Royo, et al.
Pageof 15

Showing results (131-140 of 149) with videos related to

Sort By:
Pageof 15
Blood|October 14, 2010
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemiaYair Herishanu, Patricia Pérez-Galán, Delong Liu, et al.
Blood|November 14, 2022
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenograftsDeyi Zhang, Hailey M Harris, Jonathan Chen, et al.
Blood|January 8, 2025
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cellsSivasubramanian Baskar, Haiyong Peng, Erika M Gaglione, et al.
Leukemia & Lymphoma|March 3, 2021
Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naïve chronic lymphocytic leukemia: a phase 2 studySanjal Desai, Clifton Mo, Erika M Gaglione, et al.
Blood|February 28, 2018
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 studyInhye E Ahn, Mohammed Z H Farooqui, Xin Tian, et al.
Blood|March 18, 2021
MARCKS affects cell motility and response to BTK inhibitors in CLLLaura Beckmann, Valeska Berg, Clarissa Dickhut, et al.
Leukemia & Lymphoma|March 11, 2017
Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemiaFie J Vojdeman, Sarah E M Herman, Nikolai Kirkby, et al.
The Lancet. Oncology|January 4, 2015
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trialMohammed Z H Farooqui, Janet Valdez, Sabrina Martyr, et al.
The Journal of Experimental Medicine|January 6, 2018
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemiaErika Tissino, Dania Benedetti, Sarah E M Herman, et al.
Cancer Research|August 24, 2012
Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical featuresAlba Navarro, Guillem Clot, Cristina Royo, et al.
Pageof 15